GHRP-6 vs GHRP-2: How Two Closely Related Hexapeptides Differ Chemically

For research use only. The two compounds discussed here are research-grade peptides studied in laboratory settings; nothing below describes human or animal use. GHRP-6 and GHRP-2 are easy to mix up, because they share most of their structure — yet they carry different names, different molecular formulas, and different catalog numbers. This article walks the GHRP-6 vs GHRP-2 chemical structure difference one position at a time. Think of it as a spot-the-difference puzzle in which only two of six building blocks actually change.

The common ground: two hexapeptides cut from the same cloth

Start with the shared ground. Both molecules are hexapeptides — short chains of exactly six amino-acid residues — and both belong to the family of synthetic growth hormone secretagogues derived from met-enkephalin. That common lineage is why the two are constantly mentioned in the same breath.

They also point at the same molecular target. Each one acts as an agonist of the growth hormone secretagogue receptor (GHSR), the receptor whose natural endogenous ligand turned out to be ghrelin. So both were built as synthetic ghrelin mimetics at that receptor — even though they were designed before ghrelin itself was characterized. If you're researching this corner of peptide chemistry, it helps to see them as siblings alongside Ipamorelin, another ghrelin-receptor peptide: same receptor neighborhood, different residue choices.

One detail rounds out the picture. Despite the met-enkephalin ancestry, neither peptide carries opioid activity. The scaffold was deliberately reshaped to keep the growth-hormone-releasing behavior seen in cell and animal models while shedding the opioid character of the parent molecule. The family resemblance is real — but it's the resemblance of two purpose-built research tools, not two accidental look-alikes.

Reading the two sequences side by side

The short answer: the two sequences are identical for the back four residues and differ only at the first two. Here they are, in the standard peptide shorthand:

• GHRP-6: His–D-Trp–Ala–Trp–D-Phe–Lys–NH₂ (GHRP-6 reference)
• GHRP-2: D-Ala–D-2-Nal–Ala–Trp–D-Phe–Lys–NH₂ (pralmorelin / GHRP-2 reference)

Two notation points, since this is where readers new to peptide chemistry get tripped up. The "D-" prefix marks a mirror-image version of the amino acid — more on why that matters below. The trailing "NH₂" is an amide cap on the tail end of the chain, a finishing touch shared by both molecules. If the way a residue chain is written out is unfamiliar, the same convention is unpacked in our explainer on how a peptide's residue sequence is written out.

Line the two up and the pattern jumps out. Positions three through six — Ala–Trp–D-Phe–Lys–NH₂ — are letter-for-letter the same in both peptides. Everything that sets GHRP-6 apart from GHRP-2 is packed into positions one and two. That's an unusually tidy contrast: two molecules with their own names, formulas, and regulatory histories that nonetheless agree on two-thirds of their sequence.

One target, two keys: the position-1 and position-2 swap

The short answer: GHRP-6 opens with histidine then D-tryptophan; GHRP-2 opens with D-alanine then a bulky two-ring residue called D-2-naphthylalanine. That's the entire molecular divergence.

Walk the two positions individually:

• Position 1: histidine (His) in GHRP-6 becomes D-alanine (D-Ala) in GHRP-2. Histidine carries a nitrogen-rich imidazole ring; D-alanine is one of the smallest residues there is, with just a methyl side chain. A large, ring-bearing residue gives way to a tiny one.
• Position 2: D-tryptophan (D-Trp) in GHRP-6 becomes D-2-naphthylalanine (D-2-Nal) in GHRP-2 — a non-natural residue whose side chain is a fused two-ring naphthalene system. This is the D-2-naphthylalanine substitution that peptide chemists point to as the signature feature of GHRP-2.

Both swapped positions sit at the front of the molecule, and both peptides aim at the same GHSR target — part of the broad G-protein-coupled receptor superfamily mapped in our overview of the GPCR family these receptors belong to. In a sense, the two peptides are differently cut keys for the same lock.

Does the swap change anything measurable? In a classic in-vitro comparison, researchers tested both peptides on rat primary pituitary cells and reported that GHRP-2 was the more potent growth-hormone secretagogue in that cell-culture model, while both acted through the same receptor system. That observation is strictly a structural-pharmacology finding in cultured cells — a statement about how the position-2 residue influences receptor engagement in the lab, not a claim about any outcome in a living subject.

Molecular formula and mass: counting the difference

The short answer: the two peptides don't share a molecular formula, and GHRP-2 is the lighter of the two.

• GHRP-6: C₄₆H₅₆N₁₂O₆, molar mass roughly 873 g/mol (GHRP-6 reference).
• GHRP-2: free-peptide formula C₄₅H₅₅N₉O₆, molar mass roughly 818 g/mol (pralmorelin reference), a value also catalogued in the PubChem record for GHRP-2.

The most telling number here is the nitrogen count: twelve nitrogen atoms in GHRP-6 against nine in GHRP-2. Where does the gap come from? Trace it back to the two swapped residues. GHRP-6's histidine contributes an imidazole ring (two extra nitrogens), and its D-tryptophan contributes an indole ring (one nitrogen). GHRP-2 replaces those with D-alanine, which has no ring nitrogen, and a naphthalene system, which is an all-carbon two-ring structure. Strip out the nitrogen-bearing rings and you account for exactly the N12-to-N9 difference. The two-residue swap, in other words, is also a quiet bit of elemental bookkeeping.

Why the shared tail and the D-amino acids matter

The short answer: the conserved back end is the part both molecules use to grip the receptor, and the scattered D-amino acids are a deliberate stability trick.

That shared C-terminal stretch — Ala–Trp–D-Phe–Lys–NH₂, plus the amide cap — is no coincidence. It forms the common pharmacophore, the portion of the molecule most responsible for engaging the GHSR. Hold that tail constant while varying the front two positions, and you have exactly the method medicinal chemists use to probe which parts of a peptide do the binding and which parts can be tuned.

The D-amino acids are the other shared design choice worth understanding. Natural proteins are built almost entirely from L-amino acids, the form the body's enzymes are tuned to recognize and cleave. Swap in mirror-image D-amino acids at chosen positions and the peptide becomes harder for those enzymes to take apart — a standard way to improve the metabolic stability of a synthetic peptide in research settings (GHRP-6 reference). Both molecules lean on this trick: GHRP-6 with its D-Trp and D-Phe, GHRP-2 with its D-Ala, D-2-Nal, and D-Phe.

One last divergence sits outside the chemistry itself: regulatory identity. GHRP-2, under the name pralmorelin, has a recognized clinical footprint — it's marketed in Japan as a diagnostic agent for the assessment of growth hormone deficiency (pralmorelin reference). GHRP-6 has no comparable approval. And one point deserves to be explicit: because pralmorelin is an internationally recognized non-proprietary drug name, research-grade GHRP-2 material is not equivalent to, and should not be confused with, the approved pharmaceutical product of that name. A shared scaffold does not imply shared regulatory status.

Frequently Asked Questions

What is the main chemical difference between GHRP-6 and GHRP-2?

Both are six-residue peptides that share the same back four amino acids, but they differ at the first two positions. GHRP-6 starts with histidine then D-tryptophan, while GHRP-2 starts with D-alanine then a bulky non-natural residue called D-2-naphthylalanine. That two-residue swap is the whole structural story.

Do GHRP-6 and GHRP-2 have the same molecular formula?

No. GHRP-6 has the formula C₄₆H₅₆N₁₂O₆ (molar mass about 873 g/mol), while GHRP-2 has the free-peptide formula C₄₅H₅₅N₉O₆ (about 818 g/mol). GHRP-2 carries three fewer nitrogen atoms because it lacks the imidazole and second indole rings found in GHRP-6.

Are GHRP-6 and GHRP-2 related to ghrelin?

Yes, in the sense that both bind the same receptor that ghrelin binds — the growth hormone secretagogue receptor (GHSR). They were designed before ghrelin itself was discovered, so they are best described as synthetic ghrelin mimetics at that receptor.

Why do both peptides contain D-amino acids?

Natural proteins are built from L-amino acids, which the body's enzymes recognize and break down readily. Swapping in mirror-image D-amino acids at key positions makes the peptide harder for those enzymes to cleave, which is a common stability-engineering trick in synthetic peptide chemistry.

Conclusion

For all the ink spilled comparing them, the GHRP-6 vs GHRP-2 chemical structure difference comes down to two residues out of six. Hold the Ala–Trp–D-Phe–Lys–NH₂ tail constant, swap histidine and D-tryptophan for D-alanine and D-2-naphthylalanine, and you've moved from one peptide to the other — changing the molecular formula from C₄₆H₅₆N₁₂O₆ to C₄₅H₅₅N₉O₆, the mass by roughly 55 g/mol, and the catalog identity entirely. That conserved tail is a useful lens for reading the wider family of synthetic ghrelin mimetics: when two of these peptides differ, the front of the chain is usually where to look first.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.